Welcome to the e-CCO Library!

P637: Targeting mucosal healing: dose optimization of Vedolizumab in IBD patients with inadequate endoscopic response to standard dosing
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dal Buono, A.(1)*;Gabbiadini, R.(1);Migliorisi, G.(1);Solitano, V.(1);Canziani, L.(2);Repici, A.(3,4);Armuzzi, A.(1,4);
Created: Friday, 14 July 2023, 11:12 AM
P638 Stenotic Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. El Ouardi, L. Nawal, B. Imane, B. Camelia, B. Mohamed, A. Fatima Zahra

Created: Thursday, 30 January 2020, 10:12 AM
P638: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P638: BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Chimalakonda*1, J. Jones III2, R. Dockens1, J. Throup1, S. Banerjee1, I. Girgis1

Created: Friday, 22 February 2019, 9:41 AM
P638: Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Year: 2021
Source: ECCO'21 Virtual
Authors: Del Hoyo Francisco, J.(1);Millán, M.(2);Garrido-Marín, A.(1);Nos, P.(1);Barreiro-de Acosta, M.(3);Bujanda, L.(4);de la Portilla, F.(5);Aguas, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P638: Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fumery, M.(1)*;Defrance, A.(2);Roblin, X.(3);Altwegg, R.(4);Caron, B.(5);Hebuterne, X.(6);Carmen, S.(7);Meyer, A.(8);Nachury, M.(9);Laharie, D.(10);Nancey, S.(11);Le Berre, C.(12);Serrero, M.(13);Geyl, S.(14);Gilletta, C.(15);Ah Soune, P.(16);Duveau, N.(17);Uzza, M.(18);Abitbol, V.(19);Biron, A.(20);Tran Minh, M.L.(21);Paupard, T.(22);Vuitton, L.(23);Elgharabawy, Y.(2);Peyrin-biroulet, L.(5);
Created: Friday, 14 July 2023, 11:12 AM
P638: Nutritional status in paediatric Crohn’s disease patients: Does exclusive enteral nutrition help?
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Strisciuglio1*, E. Scarpato2, M.R. Serra2, F.P. Giugliano2, S. Cenni2, C. Mainolfi3, M. Martinelli2, E. Miele2

Created: Thursday, 21 February 2019, 9:14 AM
P638: Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Demyanova E.1, Vakhitov T.1, Sitkin S.*1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P639 Outcomes of a clinical psychology intervention in a UK IBD service
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Eldridge DClin Psyc, K. Strongili, M. Parkes, T. Raine

Created: Thursday, 30 January 2020, 10:12 AM
P639: Epidemiology and patient burden of rectovaginal and anovaginal fistulas in patients with Crohn’s disease: A systematic review
Year: 2021
Source: ECCO'21 Virtual
Authors: Iglay, K.(1);Bennett, D.(2,3);Kappelman, M.(4);Thai, S.(1,5);Aldridge, M.(1);Karki, C.(2);Cook, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P639: Incidence and disease presentation of inflammatory bowel disease in Denmark: initial findings from a Copenhagen IBD Inception Cohort Study
Year: 2022
Source: ECCO'22
Authors: Dorn-Rasmussen, M.(1);Attauabi, M.(2);Madsen, G.R.(3);Wewer, A.V.(1);Jansson, S.(1);Knudsen, M.M.(1);Wilkens, R.(3);Ilvemark, J.F.K.F.(2);Bjerrum, J.W.(2);Theede, K.(3);Bendtsen, F.(3);Trine, B.(3);Seidelin, J.B.(2);Burisch, J.M.(3);
Created: Friday, 11 February 2022, 3:56 PM
P639: Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Theodoraki*1, E. Orfanoudaki1, K. Foteinogiannopoulou1, E. Legaki2, M. Gazouli2, I. Koutroubakis1

Created: Friday, 22 February 2019, 9:41 AM
P639: Percutaneous drainage vs surgery as definitive treatment for anastomotic leak after intestinal resection in patients with Crohn's disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Belvedere, A.(1)*;Dajti, G.(1);Larotonda, C.(1);Angelicchio, L.(1);Rizzello, F.(2);Gionchetti, P.(2);Poggioli, G.(1);Rottoli, M.(1);
Created: Friday, 14 July 2023, 11:12 AM
P639: Switching from originator-infliximab to biosimilar-Infliximab in IBD-patients does not lead to significant changes in infliximab trough levels
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Eberl A.*1,2, Huoponen S.2, Pahikkala T.3, Arkkila P.1,2, Blom M.2, Sipponen T.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P639: Validation of the Quantum Blue® infliximab-level rapid test in clinical practice of patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, T. Schuster2, M. Löwenberg1, C. Ponsioen1, G. D'Haens1

Created: Thursday, 21 February 2019, 9:14 AM
P640 Moderate to severe endoscopic inflammation is frequent after clinical remission in pediatric ulcerative colitis: A cause for disease extension and relapse?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Sarbagili Shabat1,2, D. Weiner1, J. Wardi3, L. Abramas1, M. Yaakov1, A. Levine1,2

Created: Thursday, 30 January 2020, 10:12 AM
P640: Characteristics of elderly onset Inflammatory Bowel Disease in a cohort of Hispanics
Year: 2021
Source: ECCO'21 Virtual
Authors: Ramos, L.(1);Anca, M.(1);Feliciano, K.(1);Amaya, C.(2);Perez, A.(3);Torres, E.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P640: Evaluation of dietetic services and the impact of diet on disease activity for patients with inflammatory bowel disease at Imperial College Healthcare NHS Trust
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Sandhar*1, N. Direkze2, S. Peake2

Created: Friday, 22 February 2019, 9:41 AM
P640: Incidence, prevalence, disease phenotype and maximal therapeutic step in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
Year: 2022
Source: ECCO'22
Authors: Lakatos, L.(1);Gonczi, L.(2);Golovics, P.(3);Pandur, T.(4);David, G.(1);Erdelyi, Z.(1);Szita, I.(1);LakatosPhD, P.L.(2,5);
Created: Friday, 11 February 2022, 3:56 PM
P640: Risk of post-operative complications among Crohn’s disease patients treated pre-operatively with vedolizumab. A matched case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.Y. Kim1, K. Zaghiyan2, P. Fleshner2*

Created: Thursday, 21 February 2019, 9:14 AM